Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.79 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.73 |
| ▸ | AANAT | Q16613 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | UBE2N | P61088 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29376485 | 1.00 | MTNR1A (1.00) | MTNR1AMEN1KMT2ATRPV1AANAT | |
| SCHEMBL1725354 | 1.00 | MTNR1A (1.00) | MTNR1AMEN1KMT2ATRPV1AANAT | |
| SCHEMBL1726070 | 1.00 | MTNR1A (1.00) | MTNR1AMEN1KMT2ATRPV1AANAT | |
| SCHEMBL1726502 | 1.00 | MTNR1A (1.00) | MTNR1AMEN1KMT2ATRPV1AANAT | |
| SCHEMBL3806536 | 1.00 | MTNR1A (1.00) | MTNR1AMEN1KMT2ATRPV1AANAT | |
| SCHEMBL1063483 | 1.00 | MTNR1A (1.00) | MTNR1AMEN1KMT2ATRPV1AANAT | |
| SCHEMBL1727281 | 1.00 | MTNR1A (1.00) | MTNR1AMEN1KMT2ATRPV1AANAT | |
| SCHEMBL1066221 | 1.00 | MTNR1A (1.00) | MTNR1AMEN1KMT2ATRPV1AANAT | |
| SCHEMBL22411433 | 1.00 | MTNR1A (1.00) | MTNR1AMEN1KMT2ATRPV1AANAT | |
| SCHEMBL1725127 | 1.00 | MTNR1A (1.00) | MTNR1AMEN1KMT2ATRPV1AANAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-9486441-B2 | Compounds, compositions and methods for making the same | SIGNUM BIOSCIENCES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-8614246-B2 | Indole derivatives for treating neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2013-12-24 | — | — | US | disclosed |
| EP-2403830-A2 | INDOLE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | Centre National de la Recherche Scientifique (CNRS) (FR) | 2012-01-11 | — | — | EP | disclosed |
| US-20110319387-A1 | INDOLE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2011-12-29 | — | — | US | disclosed |
| WO-2010100133-A2 | INDOLE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-09-10 | — | — | WO | disclosed |
| WO-2009132051-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | SIGNUM BIOSCIENCES, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | SIGNUM BIOSCIENCES, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264496-A1 | Compounds, Compositions and Methods for Making the Same | PPP2CA, PPP4C, PPP6C | MTNR1A 1889/4885MEN1 3072/4885KMT2A 121/4885 |
| US-20110319387-A1 | INDOLE DERIVATIVES FOR TREATING NEURODEGENERATIVE DISEASES | SNCA, TPH1, HCRTR1 | MTNR1A 20/4885MEN1 862/4885KMT2A 2307/4885 |
| US-20170266161-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MAKING THE SAME | PPP2CA, PPP4C, PPP6C | MTNR1A 1889/4885MEN1 3072/4885KMT2A 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.